CVS Health Gains Premarket as Breakup Plan and Raised Outlook Settle In

CVS Health moved higher in early European action on November 12, 2026. On the Lang & Schwarz platform at 8:32 a.m. CET, shares reached EUR 80.97, climbing 2.23 percent over the November 11 Xetra finish of EUR 79.20. The early rise follows positive momentum on November 11, when the stock changed hands at 79.81 euros at 15:31 CET and 79.76 euros at 13:30 CET.

Investor interest has broadened after the company revealed on November 4, 2026, that it intends to divide into two publicly traded businesses by the opening half of 2028. Under the planned corporate separation, current chairman and chief executive David Joyner will head a healthcare solutions entity holding Aetna, CVS Caremark, CVS Specialty, Oak Street Health, and Signify Health. Current group president Prem Shah is set to take over as chief executive of an independent CVS Pharmacy, which will control about 9,000 retail locations, mail dispensing, MinuteClinic, and Health100 services.

The split announcement landed alongside stronger third-quarter financial figures for the period ending September 30, 2026. Quarterly revenue advanced 5.4 percent to 108.4 billion US dollars, while adjusted earnings per share reached 2.09 US dollars compared to 1.60 US dollars in the prior-year period. Adjusted operating income rose 21.2 percent to 4.194 billion US dollars, aided by improved performance in the Health Care Benefits unit, where the medical benefit ratio improved to 91.3 percent from 92.8 percent.

Following the operating recovery, leadership lifted its full-year 2026 adjusted profit guidance to at least 8.20 US dollars per share, up from an earlier expectation of 7.90 to 8.10 US dollars. Operating cash flow targets were boosted to at least 15.5 billion US dollars from a previous threshold of at least 11.5 billion US dollars, while total revenue is expected to finish at minimum at 420 billion US dollars. Executives nevertheless pointed to lingering risks, such as elevated expenses and economic headwinds.

Market analysts have also adjusted their expectations. According to Zacks, which assigns CVS Health a Rank #2 (Buy), consensus forecasts project full-year earnings of $8.21 per share, reflecting a 2.9 percent upward revision over the past 30 days. For the upcoming fiscal year, the consensus earnings estimate stands at $8.64 per share, up 1.5 percent over the last month.